### ATENT COOPERATION TRL .TY

## PCT

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference RLL-338WO	FOR FURTHER ACTION	See Form PCT/IPEA/416					
International application No. PCT/IB2004/000536	International filing date (day/month/year, 01.03.2004	Priority date (day/month/year) 28.02.2003					
International Patent Classification (IPC) or national classification and IPC A61K9/20, A61K9/30, A61K31/4439							
Applicant RANBAXY LABORATORIES LIMITED et al.							
<ol> <li>This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</li> </ol>							
2. This REPORT consists of a to	tal of 5 sheets, including this cover sheet	t.					
3. This report is also accompanie	ed by ANNEXES, comprising:						
a. 🛛 sent to the applicant ar	nd to the International Bureau) a total of 3	sheets, as follows:					
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).							
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).							
4. This report contains indications relating to the following items:							
Box No. I Basis of the	opinion						
☐ Box No. II Priority							
☐ Box No. III Non-establisi	hment of opinion with regard to novelty, ir	nventive step and industrial applicability					
☐ Box No. IV Lack of unity	of invention						
	atement under Article 35(2) with regard to citations and explanations supporting suc						
☐ Box No. VI Certain docu							
⊠ Box No. VII Certain defect	cts in the international application						
☐ Box No. VIII Certain obse	☐ Box No. VIII Certain observations on the international application						
Date of submission of the demand	Date of comple	etion of this report					
23.12.2004	08.04.2005						
Name and mailing address of the internat preliminary examining authority:	ional Authorized Office	CEF					
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 52	Hedegaard,	A					
J	sooo epina a						

10/547200

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/IB2004/000536

					DT09 Rec'd PCT/PTO 2 6 AUG 2003	
_	Во	x No. I B	asis of the	report		
1.	<ol> <li>With regard to the language, this report is based on the international application in the language in wh filed, unless otherwise indicated under this item.</li> </ol>					
		which is the internation publication	ne language itional searc ition of the i	of a translation furnish h (under Rules 12.3 an nternational application		
2.	hav	ve been fun	nished to the	ts* of the international e receiving Office in res and are not annexed to	application, this report is based on (replacement sheets whic ponse to an invitation under Article 14 are referred to in this this report):	
	Des	scription, Pa	ges			
	1-12	2		as originally filed		
	Clai	Claims, Numbers				
	1-39		received on 03.01	.2005 with letter of 23.12.2004		
		a sequenc	e listing and	l/or any related table(s)	- see Supplemental Box Relating to Sequence Listing	
3.		☐ the des☐ the clai☐ the dra	cription, pa ms, Nos. wings, shee uence listin	ts/figs		
4.	Sup	This report has been established as if (some of) the amendments annexed to this report and listed below ad not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the upplemental Box (Rule 70.2(c)).  the description, pages the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify):				
	*	If item .	4 annlies	some or all of	these sheets may be marked "supercoded "	

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/IB2004/000536

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-3, 5-7,10,13-14.17-18,21,23-26,29,31-33,36-37,39

No: Claims

Inventive step (IS) Yes: Claims

1-3, 5-7,10,13-14.17-18,21,23-26,29,31-33,36-37,39

No: Claims

Industrial applicability (IA)

Yes: Claims

1-3, 5-7,10,13-14.17-18,21,23-26,29,31-33,36-37,39

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

#### Re Item V.

1 The following documents are referred to in this communication:

D1: EP 1 004 305 A D2: WO 98/52564 A

Document D1 (see Table III) discloses stable preparations comprising a core including sodium rabeprazole (50 mg) and HPC (450 mg).

Document D2 (see example 3) discloses cores including and active drug and small amounts of low viscosity HPC (HPC-L Klucel). On p. 4, I. 4 pariprazole (= rabeprazole) is disclosed as an example of an active drug.

- The subject-matter of claims 1-3, 5-7, 10, 13-14, 17-18 and 21 (composition); 23-26, 29, 31-33 and 36 (process); and 37 and 39 (method) is novel (Art. 33(2) PCT) since a core comprising rabeprazole and at least 10% w/w of low viscosity HPC has not been disclosed in any of the available prior art documents.
- The subject-matter of claim 1 differs from D1 (see above under item 1) in that it selects a particular HPC, namely low viscosity HPC.

There is no hint in D1 (alone or in combination with any other document) that more stable compositions of rabeprazole can be obtained when including at least 10% w/w of low viscosity HPC in the core. Therefore, the subject-matter of claims 1-3, 5-7, 10, 13-14, 17-18, 21, 23-26, 29, 31-33, 36-37 and 39 is considered to involve an inventive step (Art. 33(3) PCT).

#### Re Item VII.

1 The claims should be renumbered.

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/IB2004/000536